Immunology/Inflammation
Immunology/Inflammation(免疫及炎症)
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
- 5-Lipoxygenase(11)
- Papain(1)
- PGDS(1)
- PGE synthase(24)
- SIKs(12)
- IκB/IKK(67)
- AP-1(6)
- KEAP1-Nrf2(65)
- NOD1(1)
- TLR(140)
- NF-κB(241)
- Interleukin Related(171)
- 15-lipoxygenase(2)
- Others(63)
- Aryl Hydrocarbon Receptor(36)
- CD73(14)
- Complement System(58)
- Galectin(12)
- IFNAR(25)
- NO Synthase(77)
- NOD-like Receptor (NLR)(51)
- STING(110)
- Reactive Oxygen Species(465)
- Apoptosis(802)
- FKBP(20)
- eNOS(5)
- iNOS(29)
- nNOS(20)
- Glutathione(57)
- Adaptive Immunity(222)
- Allergy(130)
- Arthritis(34)
- Autoimmunity(190)
- Gastric Disease(101)
- Immunosuppressants(39)
- Immunotherapeutics(5)
- Innate Immunity(593)
- Pulmonary Diseases(119)
- Reactive Nitrogen Species(55)
- Reactive Sulfur Species(28)
- Specialized Pro-Resolving Mediators(50)
- Cyclic GMP-AMP Synthase(2)
- BCL6(3)
- CD20(3)
- CD22
- CD28(1)
- FAP(7)
- PSMA(7)
- Nuclear Factor of activated T Cells (NFAT)(1)
- Glycoprotein VI(1)
- Tim3(2)
- Hapten(1)
- Nectin-4(2)
Immunology/Inflammation 相关产品(4245)
- GC73867TNFα activity modulator 3CAS: 2248726-53-4纯度: >98.00%
TNFα activity modulator 3(例6)是TNF活性调节剂,可抑制TNFα诱导的NF-κB活化,可用于相关研究。
- GC73943Polθ/PARP-IN-1纯度: >99.00%
Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC73818 | TLR7 agonist 20 hydrochloride | - | >99.00% | |
TLR7 agonist 20 hydrochloride是咪唑并喹啉类似物。 | ||||
| GC73822 | GNE-900 | 1200126-26-6 | >99.00% | |
GNE-900是一种ATP竞争性、选择性和口服活性的ChK1抑制剂,ChKl和ChK2的IC50分别为0.0011和1.5µM。 | ||||
| GC73865 | SNX281 | 2332803-84-4 | >99.00% | |
SNX281是一种系统活性STING激动剂,与STING蛋白结合,促进cGAS STING通路的信号转导,并增加细胞对肿瘤细胞的反应。 | ||||
| GC73867 | TNFα activity modulator 3 | 2248726-53-4 | >98.00% | |
TNFα activity modulator 3(例6)是TNF活性调节剂,可抑制TNFα诱导的NF-κB活化,可用于相关研究。 | ||||
| GC73868 | WD6305 TFA | - | >98.00% | |
WD6305 TFA是一种有效的mettl3靶向PROTAC降解剂。 | ||||
| GC73881 | PRO-6E | 2353493-69-1 | >99.00% | |
PRO-6E是一种基于小脑配体的口服活性PROTAC,在MKN-45细胞中,在1 μM时可诱导MET降解,最大降解率为81.9%。 | ||||
| GC73893 | BLU-222 | 2888704-84-3 | >98.00% | |
BLU-222是一种口服活性高选择性CDK2抑制剂。 | ||||
| GC73894 | BNT411 | 2296821-50-4 | >99.00% | |
BNT411是一种选择性TLR7激动剂,可以诱导体内和体外IFNa的释放。 | ||||
| GC73900 | HA-9104 | 2412367-83-8 | >98.00% | |
HA-9104是一种有效的选择性抑制剂,通过几乎靶向UBE2F的V30口袋来抑制cullin-5 nedylation。 | ||||
| GC73915 | PSMA-Val-Cit-PAB-Azide | 2374814-84-1 | >99.00% | |
PSMA-Val-Cit-PAB-Azide是ADC的药物接头偶联物。 | ||||
| GC73925 | YSR734 | 3032969-58-4 | >98.00% | |
YSR734(化合物21)是一种共价HDAC抑制剂,对HDAC1、HDAC2和HDAC3的IC50值分别为110 nM、154 nM和143 nM。 | ||||
| GC73928 | BDM19 | 500273-31-4 | >98.00% | |
BDM19并单独或与BCL-2/BCL-XL抑制剂Navitoclax联合诱导细胞凋亡。 | ||||
| GC73932 | WK369 | - | >99.00% | |
WK369是一种新型的BCL6小分子抑制剂,具有良好的抗卵巢癌生物活性,可诱导细胞周期阻滞和细胞凋亡。 | ||||
| GC73939 | ATPase-IN-3 | 1134203-12-5 | >99.00% | |
ATPase-IN-3(化合物6)是一种atp酶抑制剂。 | ||||
| GC73940 | BFC1108 | 692774-37-1 | >98.00% | |
BFC1108是一种小分子Bcl-2功能转换器。 | ||||
| GC73942 | NT-0249 free base | - | 不显示 | |
NT-0249 free base是一种口服活性NLRP3抑制剂。 | ||||
| GC73943 | Polθ/PARP-IN-1 | - | >99.00% | |
Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。 | ||||
| GC73950 | SC912 | - | >99.00% | |
SC912是AR-V7抑制剂(IC50 = 0.36 μM)。 | ||||
| GC73973 | MY-1442 | 3050871-87-6 | >99.00% | |
MY-1442(I-3)是微管蛋白聚合抑制剂。 | ||||
| GC73980 | GGTI-2417 | 501010-05-5 | >98.00% | |
GGTI-2417是GGTase I的强效选择性抑制剂。 | ||||
| GC73982 | NSD-IN-3 | 744260-15-9 | >98.00% | |
NSD-IN-3(化合物3)是一种强效的核受体结合SET结构域(NSD)抑制剂。 | ||||
| GC73990 | SDU-071 | - | >98.00% | |
SDU-071是BRD4-p53抑制剂的强效口服活性抑制剂。 | ||||
| GC73994 | UM4118 | 324530-92-9 | >99.00% | |
UM4118是一种铜离子载体,可以引发基于线粒体的非正规形式的细胞死亡,称为铜中毒。 | ||||
| GC73995 | XL44 | 2637949-91-6 | >98.00% | |
XL44是一种hRpn13结合物,可诱导hRpn13依赖性细胞凋亡,并通过pclaf依赖性机制限制细胞活力。 | ||||
